Page last updated: 2024-10-15

3-methyladenine

Description

N3-methyladenine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135398661
CHEMBL ID292268
CHEMBL ID4303725
CHEBI ID38635
SCHEMBL ID254058
SCHEMBL ID48369
SCHEMBL ID15764619
MeSH IDM0085737

Synonyms (89)

Synonym
nsc 66389
adenine, 3-methyl-
einecs 225-908-6
brn 0146087
6-amino-3-methylpurine
NCIOPEN2_000270
c6h7n5
nsc-66389
nsc66389
BIO1_000911
BIO1_000422
BIO1_001400
3h-purin-6-amine, 3-methyl-
inchi=1/c6h7n5/c1-11-3-10-5(7)4-6(11)9-2-8-4/h2-3h,7h2,1h
3-methyl-3h-purin-6-amine
3-methyl-3h-purin-6-ylamine
5142-23-4
3-methyladenine ,
C00913
3-methyladenine, autophagy inhibitor
1P7M
DB04104
3-methyl-3h-adenine
CHEBI:38635 ,
3-ma
3-ma nucleobase
n(3)-methyladenine
CHEMBL292268
AKOS003382321
3-methylpurin-6-amine
A7582
AKOS006228458
unii-dr88tv7snu
5-26-17-00151 (beilstein handbook reference)
dr88tv7snu ,
FT-0671432
3-methyl-d3-adenine
FT-0635560
NCGC00345447-02
S2767
BRD-K81647657-001-01-9
SCHEMBL254058
60192-57-6
n3-methyladenine
CCG-206388
SCHEMBL48369
smr002530641
MLS006010995
4AI5
HY-19312
CS-5207
SY026559
mfcd00010531
SCHEMBL15764619
FSASIHFSFGAIJM-UHFFFAOYSA-N
3-methyl-3h-purin-6-amine #
J-640198
W-202935
HB2267
AC-28818
M2518
3-methyladenine autophagy inhibitor
autophagy inhibitor, 3-ma
J-800199
DTXSID80199406
EX-A130
HMS3656P04
bdbm50488841
3,9-dihydro-3-methyl-6h-purin-6-imine
3-methyl-adenine
3-methyl-3h-purin-6-amine (acd/name 4.0)
3-methyl-3h-purin-6-ylamine (acd/name 4.0)
SW220216-1
3-methyladenine (3-ma)
Q27094948
AS-19224
BCP02452
AMY11868
CHEMBL4303725
3-methyl-7h-purin-6-imine
3-methyl-6-aminopurine
methyladenine, n(3)-
6h-purin-6-imine, 3,9-dihydro-3-methyl-
purine, 3,6-dihydro-6-imino-3-methyl-
unii-3899g64tkw
6h-purin-6-imine, 3,7-dihydro-3-methyl-
3899g64tkw ,
DTXSID901346127
PD019337

Toxicity

ExcerptReference
" Conversely, known activators of autophagy, such as lithium and rapamycin, displayed neuroprotection against this toxic compound."( Role of autophagy inhibitors and inducers in modulating the toxicity of trimethyltin in neuronal cell cultures.
Biagioni, F; Fabrizi, C; Fornai, F; Fumagalli, L; Lenzi, P; Pompili, E; Somma, F, 2012
)
" Both TBQ and TBE are cytotoxic, but their toxic mechanisms have not been fully characterized."( Protective roles of aldo-keto reductase 1B10 and autophagy against toxicity induced by p-quinone metabolites of tert-butylhydroquinone in lung cancer A549 cells.
Bunai, Y; Chen, H; El-Kabbani, O; Endo, S; Hara, A; Ikari, A; Matsunaga, T; Nishiyama, A; Soda, M; Suyama, M; Tajima, K; Takemura, M, 2015
)
" Docetaxel produced significant toxicity in PC-3 cells but was not toxic to LNCaP cells."( Paradoxical effects of the autophagy inhibitor 3-methyladenine on docetaxel-induced toxicity in PC-3 and LNCaP prostate cancer cells.
Anoopkumar-Dukie, S; Bernaitis, N; Chess-Williams, R; Christie, D; Davey, AK; Forbes, A; McDermott, CM; McFarland, AJ; Perkins, AV; Pickard, RD; Spencer, BH, 2015
)
"Inhibition of early steps of autophagy by 3-MA or Beclin 1 knockdown decreased the toxic effect of arsenic trioxide (ATO) in GBM cell lines."( Impact of autophagy inhibition at different stages on cytotoxic effect of autophagy inducer in glioblastoma cells.
Bi, Y; Chen, X; Cho, K; Hou, X; Li, C; Liu, H; Liu, Y; Peng, F; Shen, C; Wang, K; Wang, X; Yang, Z; Zhang, J; Zhang, W; Zhang, X; Zhao, S; Zheng, Z; Zhong, C; Zou, H, 2015
)
" The toxic response in cells either pretreated with PCB 52 and then treated with GO or concurrently treated with GO and PCB 52 did not differ significantly from the toxic response in the cells treated with PCB 52 alone."( Graphene Oxide Attenuates the Cytotoxicity and Mutagenicity of PCB 52 via Activation of Genuine Autophagy.
Chen, S; Dai, H; Deng, Z; Du, H; Hei, TK; Liu, Y; Nie, Y; Wang, J; Wang, M; Wang, X; Wu, L; Xu, A, 2016
)
" MTX was more toxic in equivalent concentrations in all cytotoxicity tests performed [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide reduction, neutral red uptake, and lactate dehydrogenase release assays] and times tested (24 and 48 h)."( Naphthoquinoxaline metabolite of mitoxantrone is less cardiotoxic than the parent compound and it can be a more cardiosafe drug in anticancer therapy.
Bastos, ML; Carvalho, F; Carvalho, RA; Costa, VM; Gomes, AS; Pinto, M; Reis-Mendes, A; Remião, F; Sousa, E, 2017
)
"Oligomerization of human islet amyloid polypeptide (hIAPP) is toxic and contributes to progressive reduction of β cell mass in patients with type 2 diabetes mellitus."( ROS‑mediated autophagy through the AMPK signaling pathway protects INS‑1 cells from human islet amyloid polypeptide‑induced cytotoxicity.
Jin, Y; Li, X; Xia, G; Xiao, J; Zhou, J; Zhu, T, 2018
)
" Our data demonstrated that while the animals in the recovery state showed a significant trend to decreased oxidative damage, normalized antioxidative system and ameliorated endoplasmic reticulum (ER) stress compared with Dox-induced toxic model, 3-MA treatment abrogated the recovering process, resulting in sustained oxidative and ER stress and neuronal apoptosis."( The involvement of autophagic flux in the development and recovery of doxorubicin-induced neurotoxicity.
Dang, R; Guo, Y; Jiang, P; Li, G; Liu, Y; Qiao, Y; Xie, R; Xu, P; Zhou, X, 2018
)
" Consistently, a lack of MKP-5 aggravated the adverse effects of lipotoxicity."( MKP-5 Relieves Lipotoxicity-Induced Islet β-Cell Dysfunction and Apoptosis via Regulation of Autophagy.
Jiao, P; Li, L; Ma, J; Ma, Y; Teng, W; Tian, Y; Wang, W; Yan, W; Zhao, T, 2020
)

Compound-Compound Interactions

MPS combined with 3-methyladenine or chloroquine reduced the adhesion rate of AC trophozoites rather than MPS containing only polyhexamethylene biguanide.

ExcerptReference
" The aim of this study is to investigate the synergistic anticancer effect of resveratrol in combination with cisplatin and the potential anticancer mechanisms involved in A549 cells."( The synergistic effect of resveratrol in combination with cisplatin on apoptosis via modulating autophagy in A549 cells.
Hu, S; Kong, H; Li, X; Wang, H; Xie, W; Xu, R; Ye, L; Zeng, X, 2016
)
"The aim of the study was to evaluate the effect of multipurpose contact lens (CL) solution (MPS) combined with autophagy inhibitors on the adhesion properties of Acanthamoeba castellanii (AC) trophozoites to silicone hydrogel CLs."( Effect of Multipurpose Solution Combined With Autophagy Inhibitors on Adhesion of Acanthamoeba trophozoites to Silicone Hydrogel Contact Lenses.
Lee, DI; Lee, JE; Lee, JS; Lee, SM; Park, SH; Yu, HS, 2017
)
" We analyzed the efficacy of MPS combined with autophagy inhibitors, 3-methyladenine (0."( Effect of Multipurpose Solution Combined With Autophagy Inhibitors on Adhesion of Acanthamoeba trophozoites to Silicone Hydrogel Contact Lenses.
Lee, DI; Lee, JE; Lee, JS; Lee, SM; Park, SH; Yu, HS, 2017
)
"MPS combined with 3-methyladenine or chloroquine reduced the adhesion rate of AC trophozoites rather than MPS containing only polyhexamethylene biguanide."( Effect of Multipurpose Solution Combined With Autophagy Inhibitors on Adhesion of Acanthamoeba trophozoites to Silicone Hydrogel Contact Lenses.
Lee, DI; Lee, JE; Lee, JS; Lee, SM; Park, SH; Yu, HS, 2017
)
" Therefore, we investigated the characteristics of autophagic response to ARN-509 treatment and evaluated the potential effect of a combination with autophagy inhibition."( Apalutamide in combination with autophagy inhibitors improves treatment effects in prostate cancer cells.
Eberli, D; Kranzbühler, B; Mortezavi, A; Salemi, S; Sulser, T, 2020
)
" Cells were treated with ARN-509 (50 µM) alone or in combination with the autophagy inhibitors 3-methyladenine (3MA, 5 mM) or chloroquine (Chl, 20 µM) or with ATG5 siRNA knock-down."( Apalutamide in combination with autophagy inhibitors improves treatment effects in prostate cancer cells.
Eberli, D; Kranzbühler, B; Mortezavi, A; Salemi, S; Sulser, T, 2020
)
" Furthermore, in combination with autophagy inhibitors, ARN-509 provided a significantly elevated antitumor effect, thus providing a new therapeutic approach potentially translatable to patients."( Apalutamide in combination with autophagy inhibitors improves treatment effects in prostate cancer cells.
Eberli, D; Kranzbühler, B; Mortezavi, A; Salemi, S; Sulser, T, 2020
)

Bioavailability

ExcerptReference
" NVP-BEZ235 is a novel, orally bioavailable dual PI3K/mTOR inhibitor that has exhibited promising activity against HCC in preclinical models."( Dual PI3K/mTOR inhibitor NVP-BEZ235-induced apoptosis of hepatocellular carcinoma cell lines is enhanced by inhibitors of autophagy.
Chang, Z; Guo, H; Guo, X; Jia, X; Jin, J; Luo, F; Shi, G; Song, Y, 2013
)
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
"Curcumin, a polyphenolic compound, is a well-known anticancer agent, although its poor bioavailability remains a big concern."( Curcumin induces autophagic cell death in human thyroid cancer cells.
Bao, J; Cheng, X; Wang, X; Wang, Y; Wu, J; Wu, L; Xu, S; Yu, H; Zhang, L, 2022
)

Dosage Studied

ExcerptReference
" The inhibitory effect of NE was partially antagonized by propranolol but not by prazosin, and dose-response curves with BRL-37344 (a beta(3)-agonist), isoproterenol (a beta(1)/beta(2)-agonist) and dobutamide (a beta(1)-agonist) were consistent with the involvement of a beta(3)-adrenergic receptor."( Differentiation-dependent inhibition of proteolysis by norepinephrine in brown adipocytes.
Desautels, M; Heal, S, 1999
)
" It was concluded that under controlled study conditions: (1) 1-OHP, S-PMA and t,t-MA are useful biomarkers that could differentiate exposure between smoking conventional and EHCSS cigarettes or between smoking conventional cigarettes and no smoking; between S-PMA and t,t-MA, the former appeared to be more sensitive; (2) 3-MeAd could only differentiate between smoking conventional cigarettes and no smoking; the results for 3-EtAd were not conclusive because contradictory results were observed; (3) 8-OHdG had a questionable association with smoking and therefore the utility of this biomarker for smoking-related exposure could not be established; and (4) urinary excretion of thioethers as a biomarker lacked sensitivity to demonstrate a clear dose-response relationship in conventional cigarette smokers, although it could differentiate the excretion levels between those subjects who smoked a conventional cigarette and those who stopped smoking."( Evaluation of urinary 1-hydroxypyrene, S-phenylmercapturic acid, trans,trans-muconic acid, 3-methyladenine, 3-ethyladenine, 8-hydroxy-2'-deoxyguanosine and thioethers as biomarkers of exposure to cigarette smoke.
Engl, J; Feng, S; Jin, Y; Kinser, R; Liang, Q; Riedel, K; Roethig, HJ; Scherer, G; Urban, M,
)
" Dosing and time course experiments showed that 3-MA's ability to activate lipolysis was more sensitive than its inhibitory effect on autophagy."( The autophagic inhibitor 3-methyladenine potently stimulates PKA-dependent lipolysis in adipocytes.
Heckmann, BL; Liu, J; Yang, X; Zhang, X, 2013
)
" The results showed that four types of aqueous extracts significantly induced the formation of N7-MeG and N3-MeA in a linear dose-response manner."( Direct-acting DNA alkylating agents present in aqueous extracts of areca nut and its products.
Chao, MR; Hu, CW, 2012
)
" Finally, the in vivo mice bearing a SiHa xenograft, LicA dosed at 10 or 20 mg/kg significantly inhibited tumor growth."( Licochalcone A induces autophagy through PI3K/Akt/mTOR inactivation and autophagy suppression enhances Licochalcone A-induced apoptosis of human cervical cancer cells.
Hsieh, YH; Hsueh, JT; Lee, CH; Lin, CL; Tsai, JP; Ying, TH, 2015
)
" Both CQ and 3-MA were synergistic with VCR to inhibit the growth of retinoblastoma cells and the combinational use significantly reduced the dosage of each drug."( Low concentrations of chloroquine and 3-methyladenine suppress the viability of retinoblastoma cells synergistically with vincristine independent of autophagy inhibition.
Chen, X; Chen, YH; Jiang, PF; Li, LJ; Li, W; Shen, HQ; Zheng, XY, 2015
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pathways (5)

PathwayProteinsCompounds
DNA Repair25547
Base Excision Repair3523
Base-Excision Repair, AP Site Formation1716
Depurination107
Cleavage of the damaged purine47

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
EWS/FLI fusion proteinHomo sapiens (human)Potency0.21800.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, DNA-3-methyladenine glycosylase IEscherichia coliKd42.000042.000042.000042.0000AID977611
Chain A, DNA-3-METHYLADENINE GLYCOSYLASE IStaphylococcus aureus subsp. aureus MSSA476Kd710.0000220.0000710.00001,200.0000AID977611
Chain A, Dna-3-methyladenine Glycosylase IStaphylococcus aureusKd710.0000220.0000710.00001,200.0000AID977611
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (57)

Assay IDTitleYearJournalArticle
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2012Acta crystallographica. Section F, Structural biology and crystallization communications, Jun-01, Volume: 68, Issue:Pt 6
A model for 3-methyladenine recognition by 3-methyladenine DNA glycosylase I (TAG) from Staphylococcus aureus.
AID1409704Cytoprotective activity against H2O2-induced necrosis in human HL60 cells assessed as increase in cell viability at 1 to 5 mM incubated for 1 hr followed by H2O2 stimulation measured after 3 hrs by Alamar blue assay2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Indolylmaleimide Derivative IM-17 Shows Cardioprotective Effects in Ischemia-Reperfusion Injury.
AID1687057Inhibition of autophagy in human PANC-1 cells cultured in nutrient-deprived medium assessed as inhibition of LC3-2 expression at 5 mM after 6 hrs by Western blot analysis relative to control
AID155652Inhibition of Phosphatidylinositol 4-kinase at the ATP binding site at 500 uM1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Purine derivatives as competitive inhibitors of human erythrocyte membrane phosphatidylinositol 4-kinase.
AID754271Binding affinity to GST-tagged Grb2 SH3C domain (unknown origin) using biotinylated Gab2b peptide as substrate at 5 mM by SDS-PAGE analysis2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Novel inhibitors of a Grb2 SH3C domain interaction identified by a virtual screen.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2003The Journal of biological chemistry, Nov-28, Volume: 278, Issue:48
Solution structure and base perturbation studies reveal a novel mode of alkylated base recognition by 3-methyladenine DNA glycosylase I.
AID1811Experimentally measured binding affinity data derived from PDB2003The Journal of biological chemistry, Nov-28, Volume: 278, Issue:48
Solution structure and base perturbation studies reveal a novel mode of alkylated base recognition by 3-methyladenine DNA glycosylase I.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,233)

TimeframeStudies, This Drug (%)All Drugs %
pre-199064 (5.19)18.7374
1990's67 (5.43)18.2507
2000's146 (11.84)29.6817
2010's833 (67.56)24.3611
2020's123 (9.98)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.08%)5.53%
Reviews11 (0.88%)6.00%
Case Studies1 (0.08%)4.05%
Observational0 (0.00%)0.25%
Other1,242 (98.96%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]